eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
2/2023
vol. 25
 
Share:
Send email
Share:
Review paper

Steroidogenesis inhibitors in the treatment of nonoperative Cushing’s syndrome – a literature review

Magdalena Kamińska
1
,
Adam Strzoda
2
,
Anna Strzoda
2
,
Agata Strzoda
3
,
Wojciech Sowiński
2
,
Michał Zdybel
2
,
Agata Juda
2
,
Kornelia Rojek
2
,
Agnieszka Polak
1

1.
Department of Endocrinology, Diabetology and Metabolic Diseases, Medical University of Lublin, Lublin, Poland
2.
Student Scientific Society at Department of Endocrinology, Diabetology and Metabolic Diseases, Medical University of Lublin, Lublin, Poland
3.
Salus Aegroti Student Scientific Society at Departament of Physiology, Faculty of Medicine of Cardinal Stefan Wyszynski University in Warsaw, Warsaw, Poland
Family Medicine & Primary Care Review 2023; 25(2): 212–216
DOI: https://doi.org/10.5114/fmpcr.2023.127682
Online publish date: 2023/06/26
Article file
- 15 FM&PCR 2 23 - R - Kaminska -1322 - Seroidogenesis.pdf  [0.49 MB]
Get citation
 
PlumX metrics:
 
1. Sharma ST, Nieman LK, Feelders RA. Cushing’s syndrome: epidemiology and developments in disease management. Clin Epidemiol 2015; 7: 281–293.
2. Nishioka H, Yamada S. Cushing’s Disease. J Clin Med 2019; 8(11): 1951.
3. Braun LT, Rubinstein G, Zopp S, et al. Recurrence after pituitary surgery in adult Cushing’s disease: a systematic review on diagnosis and treatment. Endocrine 2020; 70(2): 218–231.
4. Cai Y, Ren L, Tan S, et al. Mechanism, diagnosis, and treatment of cyclic Cushing’s syndrome: a review. Biomed Pharmacother 2022; 153: 113301.
5. Pivonello R, Simeoli C, Di Paola N, et al. Cushing’s disease: adrenal steroidogenesis inhibitors. Pituitary 2022; 25(5): 726–732.
6. Tritos NA. Adrenally Directed Medical Therapies for Cushing Syndrome. J Clin Endocrinol Metab 2021; 106(1): 16–25.
7. Castinetti F, Nieman LK, Reincke M, et al. Approach to the Patient Treated with Steroidogenesis Inhibitors. J Clin Endocrinol Metab 2021; 106(7): 2114–2123.
8. Constantinescu SM, Driessens N, Lefebvre A, et al. Etomidate infusion at low doses is an effective and safe treatment for severe Cushing’s syndrome outside intensive care. Eur J Endocrinol 2020; 183(2): 161–167.
9. Baudry C, Coste J, Bou Khalil R, et al. Efficiency and tolerance of mitotane in Cushing’s disease in 76 patients from a single center. Eur J Endocrinol 2012; 167(4): 473–481.
10. Varlamov EV, Han AJ, Fleseriu M. Updates in adrenal steroidogenesis inhibitors for Cushing’s syndrome – a practical guide. Best Pract Res Clin Endocrinol Metab 2021; 35(1): 101490.
11. Castinetti F, Guignat L, Giraud P, et al. Ketoconazole in Cushing’s disease: is it worth a try? J Clin Endocrinol Metab 2014; 99(5): 1623–1630.
12. Pivonello R, Leo M, de, Cozzolino A, et al. The Treatment of Cushing’s Disease. Endocr Rev 2015; 36(4): 385–486.
13. Pivonello R, Ferrigno R, Martino MC, de, et al. Medical Treatment of Cushing’s Disease: An Overview of the Current and Recent Clinical Trials. Front Endo-crinol (Lausanne) 2020; 11: 648.
14. Young J, Bertherat J, Vantyghem MC, et al. Hepatic safety of ketoconazole in Cushing’s syndrome: results of a Compassionate Use Programme in France. Eur J Endocrinol 2018; 178(5): 447–458.
15. “Annex I Summary Of Product Characteristics” – Ketoconazole [cited 14.03.2023]. Available from URL: https://www.ema.europa.eu/en/documents/product-information/ketoconazole-hra-epar-product-information_en.pdf .
16. Newell-Price J, Nieman LK, Reincke M, et al. Endocrinology in the time of COVID-19: management of Cushing’s syndrome. Eur J Endocrinol 2020; 183(1): G1–G7.
17. Daniel E, Newell-Price JD. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing’s syndrome. Eur J Endocrinol 2015; 172(6): R263–R280.
18. Creemers SG, Feelders RA, Jong FH, de, et al. Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing’s Syn-drome Treatment. J Clin Endocrinol Metab 2021; 106(4): e1618–e1630.
19. Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol 2021; 9(12): 847–875.
20. Fleseriu M, Pivonello R, Elenkova A, et al. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing’s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial [published correction appears in Lancet Diabetes Endocrinol. Lancet Diabetes Endocrinol 2019; 7(11): 855–865.
21. Pivonello R, Zacharieva S, Elenkova A, et al. Levoketoconazole in the treatment of patients with endogenous Cushing’s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). Pituitary 2022; 25: 911–926.
22. Pivonello R, Elenkova A, Fleseriu M, et al. Levoketoconazole in the Treatment of Patients with Cushing’s Syndrome and Diabetes Mellitus: Results from the SONICS Phase 3 Study. Front Endocrinol (Lausanne) 2021; 12: 595894.
23. Nieman LK, Boscaro M, Scaroni CM, et al. Metyrapone Treatment in Endogenous Cushing’s Syndrome: Results at Week 12 from PROMPT, a Prospective International Multicenter, Open-Label, Phase III/IV Study. J Endocr Soc 2021; 5(Suppl 1): A515.
24. Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 1991; 35(2): 169–178.
25. Daniel E, Aylwin S, Mustafa O, et al. Effectiveness of Metyrapone in Treating Cushing’s Syndrome: A Retrospective Multicenter Study in 195 Patients. J Clin Endocrinol Metab 2015; 100(11): 4146–4154.
26. Bass IR, Leiter A, Pozharny Y, et al. Cushing Disease Treated Successfully with Metyrapone During Pregnancy. AACE Clin Case Rep 2021; 8(2): 78–81.
27. Valassi E, Crespo I, Gich I, et al. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing’s syndrome. Clin Endocrinol (Oxf) 2012; 77(5): 735–742.
28. Mitotan (mitotane) opis substancji. Indeks Leków MP [cited 7.12.2023]. Available from URL: https://indeks.mp.pl/desc.php?id=7038 (in Polish).
29. Daffara F, Francia S, de, Reimondo G, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 2008; 15(4): 1043–1053.
30. Etomidat. Medycyna Praktyczna [cited 7.12.2023]. Available from URL: https://www.mp.pl/pacjent/leki/subst.html?id=280 (in Polish).
31. Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100(8): 2807–2831.
32. Preda VA, Sen J, Karavitaki N, Grossman AB. Etomidate in the management of hypercortisolaemia in Cushing’s syndrome: a review. Eur J Endocrinol 2012; 167(2): 137–143.
33. Schulte HM, Benker G, Reinwein D, et al. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing’s syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990; 70(5): 1426–1430.
34. Heyn J, Geiger C, Hinske CL, et al. Medical suppression of hypercortisolemia in Cushing’s syndrome with particular consideration of etomidate. Pituitary 2012; 15(2): 117–125.
35. Groselj U, Sikonja J, Battelino T. Osilodrostat for Cushing disease and its role in pediatrics. Horm Res Paediatr 2022, doi: 10.1159/000522054.
36. Analiza Agencji Oceny Technologii Medycznych i Taryfikacji Isturisa (osilodrostat) we wskazaniu: leczenie endogennego zespołu Cushinga u osób dorosłych Agencja Oceny Technologii Medycznych i Taryfikacji [cited 7.12.2023]. Available from URL: https://bipold.aotm.gov.pl/assets/files/wykaz_tli/RAPORTY/2020_010.pdf (in Polish).
37. Pivonello R, Fleseriu M, Newell-Price J, et al. Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 2020; 8(9): 748–761.
38. Gadelha M, Bex M, Feelders RA, et al. Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. J Clin Endocrinol Metab 2022; 107(7): e2882–e2895.
39. Fleseriu M, Biller BMK. Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples. Pituitary 2022; 25(6): 795–809.
40. Kamenický P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndrome. J Clin Endocrinol Metab 2011; 96(9): 2796–2804.
41. Corcuff JB, Young J, Masquefa-Giraud P, et al. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. Eur J Endocrinol 2015; 172(4): 473–481.
42. Amodru V, Brue T, Castinetti F. Synergistic cortisol suppression by ketoconazole-osilodrostat combination therapy. Endocrinol Diabetes Metab Case Rep 2021; 2021: 21–71.
Copyright: © 2023 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.